Last 12 months
Inside the activity.
2 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 2 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2026 Filed Aug 11, 2026 10:00 UTC |
Westlake BioPartners Fund I, L.P.10% owner
Westlake BioPartners GP I, LLC10% owner
Westlake BioPartners Fund II, L.P.10% owner
Westlake BioPartners GP II, LLC10% owner
|
ConversionSeries Seed Convertible Preferred Stock · Derivative | 938,979 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-093633 · tm2622668-1_4seq1.xml · derivative · entry 8 Westlake BioPartners Fund I, L.P. · CIK 0001749591 · 10% owner Westlake BioPartners GP I, LLC · CIK 0002007650 · 10% owner Westlake BioPartners Fund II, L.P. · CIK 0001811947 · 10% owner Westlake BioPartners GP II, LLC · CIK 0001811948 · 10% owner Westlake BioPartners Opportunity Fund I, L.P. · CIK 0001811946 · 10% owner Westlake BioPartners Opportunity GP I, LLC · CIK 0001811945 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 938,979 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · price: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2 · ownership.nature: Shares held directly by Westlake BioPartners Fund I, L.P. ("Fund I"). The general partner of Fund I is Westlake BioPartners GP I, LLC ("GP I"). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. Beth Seidenberg ("Seidenberg") is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 10:00 UTC |
Westlake BioPartners Fund I, L.P.10% owner
Westlake BioPartners GP I, LLC10% owner
Westlake BioPartners Fund II, L.P.10% owner
Westlake BioPartners GP II, LLC10% owner
|
ConversionCommon Stock | 2,066,857 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-093633 · tm2622668-1_4seq1.xml · nonDerivative · entry 7 Westlake BioPartners Fund I, L.P. · CIK 0001749591 · 10% owner Westlake BioPartners GP I, LLC · CIK 0002007650 · 10% owner Westlake BioPartners Fund II, L.P. · CIK 0001811947 · 10% owner Westlake BioPartners GP II, LLC · CIK 0001811948 · 10% owner Westlake BioPartners Opportunity Fund I, L.P. · CIK 0001811946 · 10% owner Westlake BioPartners Opportunity GP I, LLC · CIK 0001811945 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,094,813 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F5 · ownership.nature: Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Opportunity Fund"). The general partner of Opportunity Fund is Westlake BioPartners Opportunity GP I, LLC ("Opportunity GP"). Opportunity GP may be deemed to share voting and dispositive power with regard to the shares held directly by Opportunity Fund. Seidenberg is the sole managing director of Opportunity GP and has voting and dispositive power over the shares held by Opportunity Fund. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 10:00 UTC |
Westlake BioPartners Fund I, L.P.10% owner
Westlake BioPartners GP I, LLC10% owner
Westlake BioPartners Fund II, L.P.10% owner
Westlake BioPartners GP II, LLC10% owner
|
ConversionCommon Stock | 165,519 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-093633 · tm2622668-1_4seq1.xml · nonDerivative · entry 6 Westlake BioPartners Fund I, L.P. · CIK 0001749591 · 10% owner Westlake BioPartners GP I, LLC · CIK 0002007650 · 10% owner Westlake BioPartners Fund II, L.P. · CIK 0001811947 · 10% owner Westlake BioPartners GP II, LLC · CIK 0001811948 · 10% owner Westlake BioPartners Opportunity Fund I, L.P. · CIK 0001811946 · 10% owner Westlake BioPartners Opportunity GP I, LLC · CIK 0001811945 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,160,847 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Reflects a convertible note that was convertible into shares of Common Stock of the Issuer. The convertible note had a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock. F3 · ownership.nature: Shares held directly by Westlake BioPartners Fund II, L.P. ("Fund II"). The general partner of Fund II is Westlake BioPartners GP II, LLC ("GP II"). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. Seidenberg is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 10:00 UTC |
Westlake BioPartners Fund I, L.P.10% owner
Westlake BioPartners GP I, LLC10% owner
Westlake BioPartners Fund II, L.P.10% owner
Westlake BioPartners GP II, LLC10% owner
|
ConversionCommon Stock | 1,484,401 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-093633 · tm2622668-1_4seq1.xml · nonDerivative · entry 5 Westlake BioPartners Fund I, L.P. · CIK 0001749591 · 10% owner Westlake BioPartners GP I, LLC · CIK 0002007650 · 10% owner Westlake BioPartners Fund II, L.P. · CIK 0001811947 · 10% owner Westlake BioPartners GP II, LLC · CIK 0001811948 · 10% owner Westlake BioPartners Opportunity Fund I, L.P. · CIK 0001811946 · 10% owner Westlake BioPartners Opportunity GP I, LLC · CIK 0001811945 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 4,995,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F3 · ownership.nature: Shares held directly by Westlake BioPartners Fund II, L.P. ("Fund II"). The general partner of Fund II is Westlake BioPartners GP II, LLC ("GP II"). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. Seidenberg is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 10:00 UTC |
Westlake BioPartners Fund I, L.P.10% owner
Westlake BioPartners GP I, LLC10% owner
Westlake BioPartners Fund II, L.P.10% owner
Westlake BioPartners GP II, LLC10% owner
|
ConversionCommon Stock | 3,464,072 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-093633 · tm2622668-1_4seq1.xml · nonDerivative · entry 4 Westlake BioPartners Fund I, L.P. · CIK 0001749591 · 10% owner Westlake BioPartners GP I, LLC · CIK 0002007650 · 10% owner Westlake BioPartners Fund II, L.P. · CIK 0001811947 · 10% owner Westlake BioPartners GP II, LLC · CIK 0001811948 · 10% owner Westlake BioPartners Opportunity Fund I, L.P. · CIK 0001811946 · 10% owner Westlake BioPartners Opportunity GP I, LLC · CIK 0001811945 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 3,510,927 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F3 · ownership.nature: Shares held directly by Westlake BioPartners Fund II, L.P. ("Fund II"). The general partner of Fund II is Westlake BioPartners GP II, LLC ("GP II"). GP II may be deemed to share voting and dispositive power with regard to the shares held directly by Fund II. Seidenberg is the sole managing director of GP II and has voting and dispositive power over the shares held by Fund II. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 10:00 UTC |
Westlake BioPartners Fund I, L.P.10% owner
Westlake BioPartners GP I, LLC10% owner
Westlake BioPartners Fund II, L.P.10% owner
Westlake BioPartners GP II, LLC10% owner
|
ConversionCommon Stock | 1,027,635 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-093633 · tm2622668-1_4seq1.xml · nonDerivative · entry 3 Westlake BioPartners Fund I, L.P. · CIK 0001749591 · 10% owner Westlake BioPartners GP I, LLC · CIK 0002007650 · 10% owner Westlake BioPartners Fund II, L.P. · CIK 0001811947 · 10% owner Westlake BioPartners GP II, LLC · CIK 0001811948 · 10% owner Westlake BioPartners Opportunity Fund I, L.P. · CIK 0001811946 · 10% owner Westlake BioPartners Opportunity GP I, LLC · CIK 0001811945 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,944,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2 · ownership.nature: Shares held directly by Westlake BioPartners Fund I, L.P. ("Fund I"). The general partner of Fund I is Westlake BioPartners GP I, LLC ("GP I"). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. Beth Seidenberg ("Seidenberg") is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 10:00 UTC |
Westlake BioPartners Fund I, L.P.10% owner
Westlake BioPartners GP I, LLC10% owner
Westlake BioPartners Fund II, L.P.10% owner
Westlake BioPartners GP II, LLC10% owner
|
ConversionCommon Stock | 3,547,842 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-093633 · tm2622668-1_4seq1.xml · nonDerivative · entry 2 Westlake BioPartners Fund I, L.P. · CIK 0001749591 · 10% owner Westlake BioPartners GP I, LLC · CIK 0002007650 · 10% owner Westlake BioPartners Fund II, L.P. · CIK 0001811947 · 10% owner Westlake BioPartners GP II, LLC · CIK 0001811948 · 10% owner Westlake BioPartners Opportunity Fund I, L.P. · CIK 0001811946 · 10% owner Westlake BioPartners Opportunity GP I, LLC · CIK 0001811945 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 4,916,374 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2 · ownership.nature: Shares held directly by Westlake BioPartners Fund I, L.P. ("Fund I"). The general partner of Fund I is Westlake BioPartners GP I, LLC ("GP I"). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. Beth Seidenberg ("Seidenberg") is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 10, 2026 Filed Aug 11, 2026 10:00 UTC |
Westlake BioPartners Fund I, L.P.10% owner
Westlake BioPartners GP I, LLC10% owner
Westlake BioPartners Fund II, L.P.10% owner
Westlake BioPartners GP II, LLC10% owner
|
ConversionCommon Stock | 938,979 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-093633 · tm2622668-1_4seq1.xml · nonDerivative · entry 1 Westlake BioPartners Fund I, L.P. · CIK 0001749591 · 10% owner Westlake BioPartners GP I, LLC · CIK 0002007650 · 10% owner Westlake BioPartners Fund II, L.P. · CIK 0001811947 · 10% owner Westlake BioPartners GP II, LLC · CIK 0001811948 · 10% owner Westlake BioPartners Opportunity Fund I, L.P. · CIK 0001811946 · 10% owner Westlake BioPartners Opportunity GP I, LLC · CIK 0001811945 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,368,532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. F2 · ownership.nature: Shares held directly by Westlake BioPartners Fund I, L.P. ("Fund I"). The general partner of Fund I is Westlake BioPartners GP I, LLC ("GP I"). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. Beth Seidenberg ("Seidenberg") is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 12:18 UTC |
Sanofi10% owner
|
ConversionConvertible Promissory Note · Derivative | 177,978 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-345826 · ownership.xml · derivative · entry 4 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 177,978 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The principal amount of the convertible promissory note (the "Note"), together with any accrued but unpaid interest, automatically converted into shares of common stock upon the closing of the IPO at a conversion price equal to the IPO price of the common stock. F2 · price: The principal amount of the convertible promissory note (the "Note"), together with any accrued but unpaid interest, automatically converted into shares of common stock upon the closing of the IPO at a conversion price equal to the IPO price of the common stock. F2 · derivative.exercise_date: The principal amount of the convertible promissory note (the "Note"), together with any accrued but unpaid interest, automatically converted into shares of common stock upon the closing of the IPO at a conversion price equal to the IPO price of the common stock. F2 · derivative.expiration_date: The principal amount of the convertible promissory note (the "Note"), together with any accrued but unpaid interest, automatically converted into shares of common stock upon the closing of the IPO at a conversion price equal to the IPO price of the common stock. F3 · ownership.direct: Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries. F3 · ownership.nature: Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 12:18 UTC |
Sanofi10% owner
|
ConversionSeries B Preferred Stock · Derivative | 494,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-345826 · ownership.xml · derivative · entry 3 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 494,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series B Convertible Preferred Stock (the "Preferred Stock") converted automatically into shares of common stock on a one-for-one basis upon the closing of the Issuer's initial public offering on August 10, 2026 (the "IPO") without payment of consideration. F1 · price: The Series B Convertible Preferred Stock (the "Preferred Stock") converted automatically into shares of common stock on a one-for-one basis upon the closing of the Issuer's initial public offering on August 10, 2026 (the "IPO") without payment of consideration. F1 · derivative.exercise_date: The Series B Convertible Preferred Stock (the "Preferred Stock") converted automatically into shares of common stock on a one-for-one basis upon the closing of the Issuer's initial public offering on August 10, 2026 (the "IPO") without payment of consideration. F1 · derivative.expiration_date: The Series B Convertible Preferred Stock (the "Preferred Stock") converted automatically into shares of common stock on a one-for-one basis upon the closing of the Issuer's initial public offering on August 10, 2026 (the "IPO") without payment of consideration. F3 · ownership.direct: Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries. F3 · ownership.nature: Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 12:18 UTC |
Sanofi10% owner
|
ConversionCommon Stock | 177,978 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-345826 · ownership.xml · nonDerivative · entry 2 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 672,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The principal amount of the convertible promissory note (the "Note"), together with any accrued but unpaid interest, automatically converted into shares of common stock upon the closing of the IPO at a conversion price equal to the IPO price of the common stock. F3 · ownership.direct: Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries. F3 · ownership.nature: Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 12:18 UTC |
Sanofi10% owner
|
ConversionCommon Stock | 494,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-345826 · ownership.xml · nonDerivative · entry 1 Sanofi · CIK 0001121404 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 494,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series B Convertible Preferred Stock (the "Preferred Stock") converted automatically into shares of common stock on a one-for-one basis upon the closing of the Issuer's initial public offering on August 10, 2026 (the "IPO") without payment of consideration. F3 · ownership.direct: Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries. F3 · ownership.nature: Sanofi beneficially owns the securities reported herein through various wholly-owned subsidiaries. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 20:13 UTC |
5AM Ventures VI, L.P.10% owner
5AM Partners VI, LLC10% owner
5AM Opportunities II, L.P.10% owner
5AM Opportunities II (GP), LLC10% owner
PARMAR KUSH10% owner
Schwab Andrew J.10% owner
|
ConversionSeries B Preferred Stock · Derivative | 1,484,401 | $0.00 | $0.00 |
DisclosureSEC source: 0001231919-26-000869 · form4-08122026_080846.xml · derivative · entry 6 5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner 5AM Partners VI, LLC · CIK 0001829051 · 10% owner 5AM Opportunities II, L.P. · CIK 0001844401 · 10% owner 5AM Opportunities II (GP), LLC · CIK 0001873515 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Opportunities II, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,484,401 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date. F3 · ownership.nature: The securities are directly held by 5AM Opportunities II, L.P. ("Opportunities II"). 5AM Opportunities II (GP), LLC ("Opportunities II GP") is the general partner of Opportunities II and may be deemed to have sole investment and voting power over the securities held by Opportunities II. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the securities beneficially owned by Opportunities II. Each of Opportunities II GP, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 20:13 UTC |
5AM Ventures VI, L.P.10% owner
5AM Partners VI, LLC10% owner
5AM Opportunities II, L.P.10% owner
5AM Opportunities II (GP), LLC10% owner
PARMAR KUSH10% owner
Schwab Andrew J.10% owner
|
ConversionSeries A-2 Preferred Stock · Derivative | 866,018 | $0.00 | $0.00 |
DisclosureSEC source: 0001231919-26-000869 · form4-08122026_080846.xml · derivative · entry 5 5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner 5AM Partners VI, LLC · CIK 0001829051 · 10% owner 5AM Opportunities II, L.P. · CIK 0001844401 · 10% owner 5AM Opportunities II (GP), LLC · CIK 0001873515 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Opportunities II, L.P. Disclosed balance after: 0 Underlying: Common Stock · 866,018 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date. F3 · ownership.nature: The securities are directly held by 5AM Opportunities II, L.P. ("Opportunities II"). 5AM Opportunities II (GP), LLC ("Opportunities II GP") is the general partner of Opportunities II and may be deemed to have sole investment and voting power over the securities held by Opportunities II. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the securities beneficially owned by Opportunities II. Each of Opportunities II GP, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 20:13 UTC |
5AM Ventures VI, L.P.10% owner
5AM Partners VI, LLC10% owner
5AM Opportunities II, L.P.10% owner
5AM Opportunities II (GP), LLC10% owner
PARMAR KUSH10% owner
Schwab Andrew J.10% owner
|
ConversionSeries A-2 Preferred Stock · Derivative | 1,823,238 | $0.00 | $0.00 |
DisclosureSEC source: 0001231919-26-000869 · form4-08122026_080846.xml · derivative · entry 4 5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner 5AM Partners VI, LLC · CIK 0001829051 · 10% owner 5AM Opportunities II, L.P. · CIK 0001844401 · 10% owner 5AM Opportunities II (GP), LLC · CIK 0001873515 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Ventures VI, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,823,238 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date. F2 · ownership.nature: The securities are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 20:13 UTC |
5AM Ventures VI, L.P.10% owner
5AM Partners VI, LLC10% owner
5AM Opportunities II, L.P.10% owner
5AM Opportunities II (GP), LLC10% owner
PARMAR KUSH10% owner
Schwab Andrew J.10% owner
|
ConversionSeries A Preferred Stock · Derivative | 3,152,305 | $0.00 | $0.00 |
DisclosureSEC source: 0001231919-26-000869 · form4-08122026_080846.xml · derivative · entry 3 5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner 5AM Partners VI, LLC · CIK 0001829051 · 10% owner 5AM Opportunities II, L.P. · CIK 0001844401 · 10% owner 5AM Opportunities II (GP), LLC · CIK 0001873515 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Ventures VI, L.P. Disclosed balance after: 0 Underlying: Common Stock · 3,152,305 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date. F2 · ownership.nature: The securities are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 20:13 UTC |
5AM Ventures VI, L.P.10% owner
5AM Partners VI, LLC10% owner
5AM Opportunities II, L.P.10% owner
5AM Opportunities II (GP), LLC10% owner
PARMAR KUSH10% owner
Schwab Andrew J.10% owner
|
ConversionCommon Stock | 2,350,419 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001231919-26-000869 · form4-08122026_080846.xml · nonDerivative · entry 2 5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner 5AM Partners VI, LLC · CIK 0001829051 · 10% owner 5AM Opportunities II, L.P. · CIK 0001844401 · 10% owner 5AM Opportunities II (GP), LLC · CIK 0001873515 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Opportunities II, L.P. Disclosed balance after: 2,350,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date. F3 · ownership.nature: The securities are directly held by 5AM Opportunities II, L.P. ("Opportunities II"). 5AM Opportunities II (GP), LLC ("Opportunities II GP") is the general partner of Opportunities II and may be deemed to have sole investment and voting power over the securities held by Opportunities II. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Opportunities II GP and may be deemed to have shared voting and investment power over the securities beneficially owned by Opportunities II. Each of Opportunities II GP, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 20:13 UTC |
5AM Ventures VI, L.P.10% owner
5AM Partners VI, LLC10% owner
5AM Opportunities II, L.P.10% owner
5AM Opportunities II (GP), LLC10% owner
PARMAR KUSH10% owner
Schwab Andrew J.10% owner
|
ConversionCommon Stock | 4,975,543 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001231919-26-000869 · form4-08122026_080846.xml · nonDerivative · entry 1 5AM Ventures VI, L.P. · CIK 0001753037 · 10% owner 5AM Partners VI, LLC · CIK 0001829051 · 10% owner 5AM Opportunities II, L.P. · CIK 0001844401 · 10% owner 5AM Opportunities II (GP), LLC · CIK 0001873515 · 10% owner PARMAR KUSH · CIK 0001664281 · 10% owner Schwab Andrew J. · CIK 0001598549 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By 5AM Ventures VI, L.P. Disclosed balance after: 4,975,543 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis. The Series A Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock had no expiration date. F2 · ownership.nature: The securities are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VI and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VI. Each of Partners VI, Dr. Parmar, and Mr. Schwab disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| August 06, 2026 Filed Aug 11, 2026 00:00 UTC |
SMITH TODD NDirector
|
GrantDirector Stock Option (right to buy) · Derivative | 105,542 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001523672-26-000007 · form4-08102026_080806.xml · derivative · entry 1 SMITH TODD N · CIK 0001523672 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,542 Underlying: Common Stock · 105,542 shares Expires 2036-08-05 F1 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments after May 30, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.